About PHYSIOSEQ
Our history
Who We Are
how we began
Founded in 2018, PHYSIOSEQ is a Northern California–based biotechnology company providing precision medicine services to leading industry and academic partners. Originally established as a data analysis and consulting firm, PHYSIOSEQ has grown from these humble beginnings into a medium-sized, full-service biotech company specializing in state-of-the-art technologies for spatial RNA profiling and single-cell sequencing.
Supported by these platforms and a multidisciplinary team of mathematicians and scientists, PHYSIOSEQ helps identify new drug targets and evaluate the effectiveness of existing therapies across a range of diseases. PHYSIOSEQ complements its laboratory operations with a modern, fully equipped clinical trials facility, supporting its translational research endeavors.
Looking ahead, PHYSIOSEQ plans to develop direct-to-consumer platforms, expand its research catchment area to include Southern California, and continue developing its Mexico facility in Hermosillo, the capital of Sonora.
Our Vision
To accelerate the world’s transition to precision medicine.
Our Mission
To make foundational discoveries that will lead to improved health through the generation and analysis of complex patient-oriented datasets, execution of cutting-edge clinical trials, and design and implementation of precision medicine tools, including direct-to-consumer and physician decision support applications.
How PHYSIOSEQ is Organized
As of 2024, Physioseq is organized into three divisions, Physioseq Precision Medicine, MAVE Body and Skin Institute, and UMICRO.
PHYSIOSEQ Precision Medicine is focused on providing cutting edge sequencing (e.g. spatial sequencing, advanced scRNA-seq, metatranscriptomics, etc) and glycoproteomic profiling services to leading pharmaceutical partners to support ancillary studies to ongoing clinical projects. It also designs and runs basic discovery research projects to identify novel drug targets for various diseases, especially immune-mediated diseases. One common task performed by PHYSIOSEQ scientists is to characterize patients who fail to respond to a particular therapy and to construct predictive classifiers that can identify these patients based on molecular signatures (transcriptomic, proteomic, glycomic, etc). PHYSIOSEQ is highly skilled at building models from large -omic data sets, utilizing novel strategies to prevent overfitting and innovative engineering methods for feature selection.
The MAVE Body and Skin Institute is charged with conducting the clinical studies and collecting the patients samples that are analyzed by PHYSIOSEQ Precision Medicine. MAVE operates out of a beautifully designed medical clinic that is equipped with modern state-of-the-art technologies. MAVE has expertise with all aspects of clinical trial management and has been highly successful at patient recruitment, capable of conducting large 100+ patient clinical studies.
UMICRO currently provides microbiome sequencing services for industry and academic partners. It also has a direct-to-consumer platform for home microbiome testing and purchase of prebiotic and probiotic products.